Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) CEO Sanj K. Patel sold 136,124 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at approximately $1,616,257.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kiniksa Pharmaceuticals Stock Up 0.8 %
Shares of NASDAQ KNSA opened at $26.12 on Friday. The firm’s 50-day moving average price is $19.97 and its two-hundred day moving average price is $19.47. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.12 and a 52-week high of $27.88. The stock has a market capitalization of $1.85 billion, a P/E ratio of 237.48 and a beta of 0.38.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The business had revenue of $108.30 million for the quarter, compared to the consensus estimate of $90.60 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 3.10%. The business’s revenue was up 51.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.05 earnings per share for the current year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on KNSA shares. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Evercore ISI increased their target price on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Wells Fargo & Company started coverage on Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They set an “overweight” rating and a $34.00 price target on the stock. Four research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $32.00.
Check Out Our Latest Analysis on Kiniksa Pharmaceuticals
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
- Five stocks we like better than Kiniksa Pharmaceuticals
- Stock Market Upgrades: What Are They?
- Why Call Options Volume for These 2 Stocks Spiked Together
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- MarketBeat Week in Review – 7/22 – 7/26
- With Risk Tolerance, One Size Does Not Fit All
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.